KBY Biotech Indexv0.0.34
Search
← Pipeline|VVY-8289

VVY-8289

Phase 2/3
By Vivoryon
Source: Trial-derived·Trials: 2
Modality
Degrader
MOA
SOS1i
Target
PCSK9
Pathway
NF-κB
NASH
Development Pipeline
Preclinical
~Apr 2019
→ ~Jul 2020
Phase 1
~Oct 2020
→ ~Jan 2022
Phase 2
Apr 2022
→ Jan 2026
Phase 2Current
NCT06068493
1,080 pts·NASH
2025-04→2026-01·Recruiting
NCT04466481
2,103 pts·NASH
2022-04→2025-03·Terminated
3,183 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-03-191.0y agoPh3 Readout· NASH
2026-01-093mo agoPh3 Readout· NASH
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026
P2/3
Termina…
P2/3
Recruit…
Catalysts
Ph3 Readout
2025-03-19 · 1.0y ago
NASH
Ph3 Readout
2026-01-09 · 3mo ago
NASH
RecruitingTerminated|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT06068493Phase 2/3NASHRecruiting1080LiverFat
NCT04466481Phase 2/3NASHTerminated2103LiverFat
Competitors (10)
DrugCompanyPhaseTargetMOA
PFE-2901PfizerPhase 2AHRSOS1i
MRK-1380Merck & CoPreclinicalSHP2SOS1i
TerarelsinAbbViePreclinicalSOS1SOS1i
ZanusertibAbbVieApprovedPCSK9KRASG12Di
DoxarapivirBristol-Myers SquibbPhase 3KRASG12CSOS1i
DSN-6862Daiichi SankyoPreclinicalIL-23SOS1i
GIL-2011Gilead SciencesPreclinicalVEGFSOS1i
GIL-4361Gilead SciencesPreclinicalPCSK9STINGag
REG-647RegeneronPreclinicalSMN2SOS1i
REG-2172RegeneronPhase 1/2PCSK9Anti-Tau